source
- Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emergeHelus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…
- J&J buys Ollin Biosciences for $2.2 billion, taps Blackstone for $750 million Phase 3 eye drug fundingJohnson & Johnson announced it will acquire Texas‑based ophthalmology biotech Ollin Biosciences, paying $2.2 billion upfront for the company and its late‑stage bispecific antibody targeting retinal…